Is Trident Texofab overvalued or undervalued?

As of 22 August 2025, the valuation grade for Trident Texofab has moved from expensive to very expensive. This indicates that the company is currently overvalued. Key ratios highlight this valuation concern, with a PE ratio of 122.14, an EV to EBITDA ratio of 70.73, and a PEG ratio of 5.80, all of which significantly exceed typical industry benchmarks.
In comparison to its peers, Trident Texofab's valuation stands out unfavorably; for instance, Lloyds Enterprises has a PE ratio of 39 and an EV to EBITDA of 96.38, while PTC India, which is classified as very attractive, boasts a PE of just 8.95 and an EV to EBITDA of 4.79. Furthermore, Trident's recent stock performance has outpaced the Sensex, with a year-to-date return of 37.19% compared to the Sensex's 4.05%, yet this does not mitigate its overvaluation status.